Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Ting
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
ROME Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The research project investigates the effects of 3TC nucleoside reverse transcriptase inhibitors (NRTIs) on cellular response and repeat RNA expression in colorectal cancer models. ROME is developing drugs that target the repetitive RNA expressed in cancers and other diseases. The investigator indicated that ROME has been optioned a license on intellectual property related to that being developed in the project and that the project will strengthen the intellectual property that is licensed to ROME. Both the company and the project are developing treatments for cancer which target repetitive RNA expression. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee further determined that the conflict could be managed with the implementation of an FCOI management plan.
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
PROJECT NARRATIVE Transcriptional and genomic analysis of epithelial cancers has revealed an abundant expression of non-coding repeat RNAs. These repeat RNAs have recently been found to behave like viruses and undergo reverse transcription and insertion in the cancer genome, and this process can be disrupted by nucleoside reverse transcriptase inhibitors (NRTIs), a class of drugs we already use in patients with viral infections. This work plans to better understand how NRTIs affect cancer cells, test their use in animal models, and understand their role in the immune response in human colon cancers.
Filed on July 01, 2019.
Tell us what you know about David Ting's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David Ting filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Ting | Massachusetts General Hospital | Conflict of Interest | ROME Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.